Back to top
more

Envista (NVST)

(Delayed Data from NYSE)

$19.41 USD

19.41
3,595,288

+0.74 (3.96%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $19.40 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaukos (GKOS) Announces PMA Submission, Boosts iStent Platform

by Zacks Equity Research

Glaukos (GKOS) submits PMA application to the FDA, which can enhance the company's deep portfolio of novel glaucoma surgical devices and sustained pharmaceuticals.

Here's Why You Should Invest in Integer Holdings (ITGR) Now

by Zacks Equity Research

Integer Holdings (ITGR) continues to gain traction from portfolio management.

Medtronic's (MDT) Emprint Ablation System Study Data Positive

by Zacks Equity Research

Medtronic's (MDT) Emprint Ablation Catheter Kit received Breakthrough Device Designation status from the FDA in April 2021 and is currently in development.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to strong segmental performance and strategic buyouts and collaborations.

Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure

by Zacks Equity Research

Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.

Omnicell (OMCL) Opens New Software Development Center in India

by Zacks Equity Research

Omnicell's (OMCL) new software development center in Bangalore, India, is expected to bolster the company's cloud-based solutions portfolio.

Abbott (ABT) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) on solid second-quarter performance and continued adoption of FreeStyle Libre worldwide.

LHC Group (LHCG) Closes Heart of Hospice Buyout, Expands Presence

by Zacks Equity Research

LHC Group (LHCG) expands its hospice presence in five states with the completion of Heart of Hospice buyout.

Here's Why You Should Retain AmerisourceBergen (ABC) Stock Now

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust pharmaceutical segment.

Thermo Fisher (TMO)-AstraZeneca to Co-Develop NGS-Based CDx

by Zacks Equity Research

Thermo Fisher's (TMO) new collaboration with AstraZeneca is intended to speed up development and introduction of targeted precision medicine therapies for patients.

Masimo (MASI) Ties Up to Educate on Prescription Opioid Overuse

by Zacks Equity Research

Masimo (MASI) partners with Penington Institute to increase awareness on overdose from prescription opioids.

QIAGEN (QGEN) to Join DAX Riding on Molecular Diagnostics Feat

by Zacks Equity Research

QIAGEN (QGEN) is experiencing significant improvements in non-COVID areas of its molecular diagnostics portfolio.

Hill-Rom (HRC) Agrees to Get Acquired by Baxter, Shares Jump

by Zacks Equity Research

The transaction is expected to close by early 2022 subject to the approval of Hill-Rom (HRC) shareholders and the fulfillment of customary closing conditions.

Abbott (ABT) Expands Vascular Portfolio With New Acquisition

by Zacks Equity Research

Abbott's (ABT) acquisition of Walk Vascular's Peripheral Thrombectomy Systems will be included into the former's existing endovascular product portfolio.

Boston Scientific (BSX) New Buyout to Aid Kidney Stone Line

by Zacks Equity Research

Boston Scientific (BSX) shares a 20-year long relationship with Lumenis and already offers the Lumenis urology laser portfolio in the United States and Japan through a distribution arrangement.

Here's Why You Should Retain Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure raises a concern.

Smith+Nephew (SNN) Releases New Features for Hip Arthroplasty

by Zacks Equity Research

Smith+Nephew (SNN) introduced the RI.HIP NAVIGATION software on the CORI Surgical System and announced the commercial availability of RI.INSIGHTS at the AAOS 2021 Annual Meeting.

Orthofix (OFIX) Fitbone Used in 1st US Pediatric Patient Implant

by Zacks Equity Research

Orthofix's (OFIX) Fitbone system is the only intramedullary limb lengthening solution to get FDA clearance for pediatric and adult use.

Abbott's (ABT) Heart Failure Device Study Outcome Favorable (Revised)

by Zacks Equity Research

Based on the favorable outcome, Abbott (ABT) files a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for the CardioMEMS device.

Here's Why You Should Retain Haemonetics (HAE) Stock for Now

by Zacks Equity Research

Strong recovery across businesses and strength in plasma franchise benefited Haemonetics (HAE) during the first quarter of fiscal 2022.

Zimmer Biomet's (ZBH) Data Favors mymobility with Apple Watch

by Zacks Equity Research

Zimmer Biomet (ZBH) presented four data presentations backing the mymobility with Apple Watch platform at the AAOS 2021 Annual Meeting.

NextGen's (NXGN) Solutions to Boost Care for Homeless Community

by Zacks Equity Research

NextGen's (NXXGN) solutions collaborate with Neighborhood Health to provide care to Nashville's homeless community through the latter's street medicine program.

Walgreens (WBA) to Stock LUCEMYRA Across US With New Pact

by Zacks Equity Research

Walgreens' (WBA) agreement with US WorldMeds finalized as recent report outlines a surge of 30% in drug overdose deaths in 2020.

Cardiovascular Systems (CSII) Introduces Diamondback in Canada

by Zacks Equity Research

The introduction of Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS in Canada will offer physicians an effective treatment option for patients with coronary artery diseases.

Here's Why You Should Retain McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.